ARVN — ARVINAS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1655759 ·
Last close
$6.82
Market Cap
$446.61M
52W High
$14.51
52W Low
$6.33
ADV30
906,642
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 500,000 | 400,000 | -59,100,000 | -53,900,000 | 607,500,000 | 88,000,000 | 93,700,000 |
| Jun 2026 | 249,700,000 | — | 164,100,000 | 169,400,000 | 675,100,000 | 94,300,000 | 113,000,000 |
| Mar 2026 | 15,600,000 | — | -63,800,000 | -57,600,000 | 647,500,000 | 87,300,000 | 260,700,000 |
| Dec 2025 | 9,500,000 | — | -74,600,000 | -67,400,000 | 717,900,000 | 142,900,000 | 284,100,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,300,000
Investing CF
$218,600,000
Financing CF
$-73,300,000
CapEx
$-1,800,000
Dividends Paid
—
Buybacks
$-74,100,000
EPS Diluted TTM
$-0.24
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,554,500,000
Inventory
—
Receivables
$5,300,000
ST Investments
$470,400,000
EBIT TTM
$-33,400,000
Pretax Income TTM
$-8,800,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$275,300,000
EBITDA
$-25,100,000
Free Cash Flow
$-46,575,000
Enterprise Value
$-131,241,112
Total Cash
$558,400,000
Total Debt
$7,400,000
Shares Out
65,485,006
Trailing EPS
$-0.08
Book Value
$7.84
ROE
-1.8%
ROA
-2.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 262,600,000 | -118,500,000 | -80,800,000 | 717,900,000 | 284,100,000 | 433,800,000 | -273,800,000 |
| Dec 2024 | 263,400,000 | -250,200,000 | -198,900,000 | 1,091,400,000 | 529,800,000 | 561,600,000 | -259,300,000 |
| Dec 2023 | 78,500,000 | -401,500,000 | -367,300,000 | 1,304,600,000 | 644,600,000 | 660,000,000 | -347,800,000 |
| Dec 2022 | 131,400,000 | -263,200,000 | -282,500,000 | 1,268,800,000 | 703,900,000 | 564,900,000 | -273,500,000 |
TTM Snapshot
Revenues TTM
$316,700,000
NetIncome TTM
$9,300,000
OpCashFlow TTM
—
Assets (Latest)
$675,100,000
Forward EPS
$-3.25
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.00 · spot: $6.77 · call volume: 364 · put volume: 40
Expected Move to 2028-01-21:
±$3.73
(55.10%) —
implied range
$3.04 –
$10.50
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | $447.10M | $5.50 | — |
| EOLS | Evolus, Inc. | $442.80M | $6.69 | — |
| INDP | Indaptus Therapeutics, Inc. | $442.36M | $3.32 | — |
| DMAC | DiaMedica Therapeutics Inc. | $452.16M | $8.38 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $437.41M | $6.62 | — |
News headlines (Yahoo Finance, 1h cache)
Arvinas to Present at Jefferies Global Healthcare Conference
2026-11-11 12:00 · Yahoo
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hemat
2026-11-04 21:01 · Yahoo
What Arvinas Bears Saw Before The Fall
2026-11-04 08:11 · Yahoo
Arvinas, Inc. Q3 2026 Earnings Call Summary
2026-11-04 02:41 · Yahoo
Arvinas Inc (ARVN) (Q3 2026) Earnings Call Highlights: Cost Cuts, $558. ...
2026-11-04 01:04 · Yahoo
Arvinas (ARVN) Q3 2026 Earnings Call Transcript
2026-11-03 21:43 · Yahoo
What Arvinas (ARVN) Said on Its Q3 Earnings Call
2026-11-03 15:14 · Yahoo
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
2026-11-03 12:40 · Yahoo
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-03 12:00 · Yahoo
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
2026-10-27 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.